The evolving view of IL-17-mediated immunity in defense against mucocutaneous candidiasis in humans

Beáta Soltész, B. Tóth, Adrien Katalin Sarkadi, M. Erdős, L. Máródi

Research output: Article

7 Citations (Scopus)

Abstract

The discovery of interleukin (IL)-17-mediated immunity has provided a robust framework upon which our current understanding of the mechanism involved in host defense against mucocutaneous candidiasis (CMC) has been built. Studies have shed light on how pattern recognition receptors expressed by innate immune cells recognize various components of Candida cell wall. Inborn errors of immunity affecting IL-17+ T cell differentiation have recently been defined, such as deficiencies of signal transducer and activator of transcription (STAT)3, STAT1, IL-12Rβ1 and IL-12p40, and caspase recruitment domain 9. Impaired receptor-ligand coupling was identified in patients with IL-17F and IL-17 receptor A (IL17RA) deficiency and autoimmune polyendocrine syndrome (APS) type 1. Mutation in the nuclear factor kappa B activator (ACT) 1 was described as a cause of impaired IL-17R-mediated signaling. CMC may be part of a complex clinical phenotype like in patients with deficiencies of STAT3, IL-12Rβ1/IL-12p40 and APS-1 or may be the only or dominant phenotypic manifestation of disease which is referred to as CMC disease. CMCD may result from deficiencies of STAT1, IL-17F, IL-17RA and ACT1. In this review we discuss how recent research on IL-17-mediated immunity shed light on host defense against mucocutaneous infection by Candida and howthe discovery of various germ-line mutations and the characterization of associated clinical phenotypes have provided insights into the role of CD4+IL-17+ lymphocytes in the regulation of anticandidal defense of body surfaces.

Original languageEnglish
Pages (from-to)348-363
Number of pages16
JournalInternational Reviews of Immunology
Volume34
Issue number4
DOIs
Publication statusPublished - máj. 25 2015

Fingerprint

Interleukin-17
Candidiasis
Interleukins
Immunity
Candida
Interleukin-17 Receptors
Phenotype
Pattern Recognition Receptors
STAT3 Transcription Factor
Germ-Line Mutation
NF-kappa B
Cell Wall
Cell Differentiation
Lymphocytes
Ligands
T-Lymphocytes
Mutation
Infection
Research

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

@article{c52ed72a8227453d937a2f1534fd7016,
title = "The evolving view of IL-17-mediated immunity in defense against mucocutaneous candidiasis in humans",
abstract = "The discovery of interleukin (IL)-17-mediated immunity has provided a robust framework upon which our current understanding of the mechanism involved in host defense against mucocutaneous candidiasis (CMC) has been built. Studies have shed light on how pattern recognition receptors expressed by innate immune cells recognize various components of Candida cell wall. Inborn errors of immunity affecting IL-17+ T cell differentiation have recently been defined, such as deficiencies of signal transducer and activator of transcription (STAT)3, STAT1, IL-12Rβ1 and IL-12p40, and caspase recruitment domain 9. Impaired receptor-ligand coupling was identified in patients with IL-17F and IL-17 receptor A (IL17RA) deficiency and autoimmune polyendocrine syndrome (APS) type 1. Mutation in the nuclear factor kappa B activator (ACT) 1 was described as a cause of impaired IL-17R-mediated signaling. CMC may be part of a complex clinical phenotype like in patients with deficiencies of STAT3, IL-12Rβ1/IL-12p40 and APS-1 or may be the only or dominant phenotypic manifestation of disease which is referred to as CMC disease. CMCD may result from deficiencies of STAT1, IL-17F, IL-17RA and ACT1. In this review we discuss how recent research on IL-17-mediated immunity shed light on host defense against mucocutaneous infection by Candida and howthe discovery of various germ-line mutations and the characterization of associated clinical phenotypes have provided insights into the role of CD4+IL-17+ lymphocytes in the regulation of anticandidal defense of body surfaces.",
keywords = "Candida, Interleukin-17, Interleukin-17 receptor-mediated signaling, Mucocutaneous candidiasis disease, Pattern-recognition receptors, Signal transducer and activator of transcription",
author = "Be{\'a}ta Solt{\'e}sz and B. T{\'o}th and Sarkadi, {Adrien Katalin} and M. Erdős and L. M{\'a}r{\'o}di",
year = "2015",
month = "5",
day = "25",
doi = "10.3109/08830185.2015.1049345",
language = "English",
volume = "34",
pages = "348--363",
journal = "International Reviews of Immunology",
issn = "0883-0185",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - The evolving view of IL-17-mediated immunity in defense against mucocutaneous candidiasis in humans

AU - Soltész, Beáta

AU - Tóth, B.

AU - Sarkadi, Adrien Katalin

AU - Erdős, M.

AU - Máródi, L.

PY - 2015/5/25

Y1 - 2015/5/25

N2 - The discovery of interleukin (IL)-17-mediated immunity has provided a robust framework upon which our current understanding of the mechanism involved in host defense against mucocutaneous candidiasis (CMC) has been built. Studies have shed light on how pattern recognition receptors expressed by innate immune cells recognize various components of Candida cell wall. Inborn errors of immunity affecting IL-17+ T cell differentiation have recently been defined, such as deficiencies of signal transducer and activator of transcription (STAT)3, STAT1, IL-12Rβ1 and IL-12p40, and caspase recruitment domain 9. Impaired receptor-ligand coupling was identified in patients with IL-17F and IL-17 receptor A (IL17RA) deficiency and autoimmune polyendocrine syndrome (APS) type 1. Mutation in the nuclear factor kappa B activator (ACT) 1 was described as a cause of impaired IL-17R-mediated signaling. CMC may be part of a complex clinical phenotype like in patients with deficiencies of STAT3, IL-12Rβ1/IL-12p40 and APS-1 or may be the only or dominant phenotypic manifestation of disease which is referred to as CMC disease. CMCD may result from deficiencies of STAT1, IL-17F, IL-17RA and ACT1. In this review we discuss how recent research on IL-17-mediated immunity shed light on host defense against mucocutaneous infection by Candida and howthe discovery of various germ-line mutations and the characterization of associated clinical phenotypes have provided insights into the role of CD4+IL-17+ lymphocytes in the regulation of anticandidal defense of body surfaces.

AB - The discovery of interleukin (IL)-17-mediated immunity has provided a robust framework upon which our current understanding of the mechanism involved in host defense against mucocutaneous candidiasis (CMC) has been built. Studies have shed light on how pattern recognition receptors expressed by innate immune cells recognize various components of Candida cell wall. Inborn errors of immunity affecting IL-17+ T cell differentiation have recently been defined, such as deficiencies of signal transducer and activator of transcription (STAT)3, STAT1, IL-12Rβ1 and IL-12p40, and caspase recruitment domain 9. Impaired receptor-ligand coupling was identified in patients with IL-17F and IL-17 receptor A (IL17RA) deficiency and autoimmune polyendocrine syndrome (APS) type 1. Mutation in the nuclear factor kappa B activator (ACT) 1 was described as a cause of impaired IL-17R-mediated signaling. CMC may be part of a complex clinical phenotype like in patients with deficiencies of STAT3, IL-12Rβ1/IL-12p40 and APS-1 or may be the only or dominant phenotypic manifestation of disease which is referred to as CMC disease. CMCD may result from deficiencies of STAT1, IL-17F, IL-17RA and ACT1. In this review we discuss how recent research on IL-17-mediated immunity shed light on host defense against mucocutaneous infection by Candida and howthe discovery of various germ-line mutations and the characterization of associated clinical phenotypes have provided insights into the role of CD4+IL-17+ lymphocytes in the regulation of anticandidal defense of body surfaces.

KW - Candida

KW - Interleukin-17

KW - Interleukin-17 receptor-mediated signaling

KW - Mucocutaneous candidiasis disease

KW - Pattern-recognition receptors

KW - Signal transducer and activator of transcription

UR - http://www.scopus.com/inward/record.url?scp=84953887296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953887296&partnerID=8YFLogxK

U2 - 10.3109/08830185.2015.1049345

DO - 10.3109/08830185.2015.1049345

M3 - Article

C2 - 26154078

AN - SCOPUS:84953887296

VL - 34

SP - 348

EP - 363

JO - International Reviews of Immunology

JF - International Reviews of Immunology

SN - 0883-0185

IS - 4

ER -